• Go to navigation
  • Go to content
AstraZeneca Clinical Trials

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca US

Main navigation

  • Home
  • Therapy Areas
    • Oncology/Infection
    • Cardiovascular
    • Gastrointestinal
    • Neuroscience
    • Respiratory/Inflammation
  • Drug Products
    • All Drug Products
  • Diseases & Conditions
    • All Diseases and Conditions
  • Glossary
  • Contact Us
  • Disclosure Commitment

You are here

  • Home
  • Last 30 days trials

  • Expand All
  • Collapse All
  • Pages
  • 1
  • 2
  • Next
  • collapse Nexium capsules Clinical Experience Investigation
  • collapse A Phase I/Ib, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9150 in Patients with Advanced/Metastatic Hepatocellular Carcinoma
  • collapse A Two-part, Randomised, Open-label, Multicentre, Phase I Study to Determine the Effect of Food on the Pharmacokinetics of Olaparib Following Single 400 mg Doses of the Capsule Formulation in Patients with Advanced Solid Tumours
  • collapse A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy
  • collapse A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients with Differentiated Thyroid Cancer
  • collapse Prevalence and risk factors in unipolar depression patients without remission after one antidepressant trial: PANTHER study.
  • collapse A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Ceftazidime-Avibactam Administered as Single and Repeated Intravenous Doses in Healthy Chinese Subjects
  • collapse A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of CAZ-AVI in Children From 3 Months of Age to <18 Years Who are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection
  • collapse A Randomised, Double-blind, Placebo-controlled Phase IIa Study to Assess the Pharmacodynamics, Safety, and Pharmacokinetics of AZD2624 When Given in Multiple Doses to Females with Polycystic Ovary Syndrome
  • collapse An Open-label, Sequential, 3-period Study to Assess the Effects of Cimetidine on the Pharmacokinetics of Naloxegol in Healthy Volunteers.
  • Pages
  • 1
  • 2
  • Next
  • Expand All
  • Collapse All

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2013